Scarica l'app Stockscreener
1.38
5.34%
0.07
Dopo l'orario di chiusura:
1.46
0.08
+5.80%
Milestone Pharmaceuticals Inc Borsa (MIST) Ultime notizie
Buybacks Report: Does Milestone Pharmaceuticals Inc offer margin of safetyMarket Activity Recap & Scalable Portfolio Growth Methods - baoquankhu1.vn
Three new hires get 123,000 Milestone stock options under Nasdaq rule - Stock Titan
Institution Moves: Is Milestone Pharmaceuticals Inc undervalued by DCF analysis2026 Earnings Impact & Free Community Consensus Stock Picks - baoquankhu1.vn
Trails Edge Capital Partners, LP Acquires 5,333,333 Shares in Mi - GuruFocus
Milestone Pharmaceuticals Announces that CARDAMYST (etripamil) Nasal Spray is Available on Express Scripts Commercial National Formularies - Bitget
Milestone Pharmaceuticals (MIST) Secures Formulary Inclusion for Cardamyst - GuruFocus
Milestone Pharmaceuticals Announces that CARDAMYST™ (etripamil) Nasal Spray is Available on Express Scripts Commercial National Formularies - The Manila Times
Express Scripts adds new PSVT nasal spray to national formularies - Stock Titan
Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Receives Consensus Recommendation of "Hold" from Brokerages - MarketBeat
MIST Stock Price, Quote & Chart | MILESTONE PHARMACEUTICALS IN (NASDAQ:MIST) - ChartMill
Milestone Pharmaceuticals gears up for Q4 print; here are the recent forecast changes from Wall Street's most accurate analysts - MSN
Milestone Pharmaceuticals (NASDAQ:MIST) Upgraded by Wall Street Zen to "Hold" Rating - marketbeat.com
Published on: 2026-03-28 09:41:33 - baoquankhu1.vn
Published on: 2026-03-28 10:15:13 - baoquankhu1.vn
Milestone Pharmaceuticals Stock: Trails Edge Discloses 4.3% Stake Amid Q4 Earnings Anticipation - AD HOC NEWS
Trails Edge files amended 4.3% stake disclosure in Milestone Pharmaceuticals (MIST) - Stock Titan
Aug Chart Watch: Is Milestone Pharmaceuticals Incs ROIC above industry averageForecast Cut & Daily Stock Trend Watchlist - baoquankhu1.vn
Milestone Pharmaceuticals Faces Increased Risk Amid Mixed Technical and Valuation Signals - Markets Mojo
Milestone Pharmaceuticals (MIST) Projected to Post Earnings on Tuesday - MarketBeat
Milestone Pharmaceuticals Inc. (MIST) GC reports 400,000-share stock option - Stock Titan
Equities Analysts Issue Forecasts for MIST FY2028 Earnings - marketbeat.com
Milestone Pharmaceuticals Faces Financial Challenges amidst Market Shifts - timothysykes.com
Regulatory Disruptions Pose Material Operational Risks for Milestone Pharmaceuticals - The Globe and Mail
MIST PE Ratio & Valuation, Is MIST Overvalued - Intellectia AI
Milestone Pharmaceuticals (NASDAQ:MIST) Posts Quarterly Earnings Results, Beats Estimates By $0.02 EPS - MarketBeat
Why Milestone Pharma Stock Is Taking A Dive Today - Sahm
Why Milestone Pharma stock is taking a dive today - MSN
How does Milestone Pharmaceuticals Inc compare to its peersIndex Update & Weekly High Conviction Trade Ideas - baoquankhu1.vn
Milestone Pharmaceuticals Inc (MIST) Q4 2025 Earnings Call Highl - GuruFocus
S P Trends: Does Milestone Pharmaceuticals Inc have consistent dividend growth2026 Top Decliners & Comprehensive Market Scan Reports - baoquankhu1.vn
Buyback Watch: What is the long term forecast for Milestone Pharmaceuticals Inc stock2026 Winners & Losers & Verified Momentum Stock Alerts - baoquankhu1.vn
Milestone Pharmaceuticals Inc (MIST) Q4 2025 Earnings Call Highlights: Strategic Advances Amid ... By GuruFocus - Investing.com Canada
Milestone Pharma Faces Earnings Hurdles Amidst Market Fluctuations - StocksToTrade
Milestone: Early CARDAMYST Launch Progress and Solid Cash Position Underscore Buy Rating and $8 Target - TipRanks
Missing Data on MIST: Insights and Analysis - timothysykes.com
Milestone Pharmaceuticals Reports 2025 Financial Results and Launch of FDA-Approved CARDAMYST Nasal Spray for PSVT - Minichart
Milestone Pharmaceuticals 2025 Annual Report: CARDAMYST™ (etripamil) Launch, Business Overview, and Key Risks - Minichart
Milestone Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Milestone Pharmaceuticals Q4 Earnings Call Highlights - MarketBeat
Earnings call transcript: Milestone Pharmaceuticals meets EPS forecast, stock dips - Investing.com
Milestone Advances CARDAMYST Launch After Landmark PSVT Approval and Bolsters Cash Runway - TipRanks
Milestone Pharmaceuticals: Fourth Quarter Earnings Overview - Bitget
Milestone Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Milestone Pharmaceuticals (MIST) Reports Strong Financial and Ma - GuruFocus
Milestone Pharmaceuticals reports Q4 EPS (16c), consensus (18c) - TipRanks
Milestone Pharmaceuticals: Q4 Earnings Snapshot - Barchart.com
Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Update on the Commercial Launch of CARDAMYST™ (etripamil) Nasal Spray for the Treatment of PSVT - The Manila Times
CARDAMYST launch and 2025 results for Milestone Pharmaceuticals (Nasdaq: MIST) - Stock Titan
Milestone Pharmaceuticals Announces FDA Approval of CARDAMYST™, the First New Treatment for PSVT in 30 Years - Quiver Quantitative
Milestone Pharmaceuticals 10‑K: $1.55M Revenue, ($0.75) EPS on $63.1M Net Loss - TradingView
Earnings Scheduled For March 20, 2026BitFuFu (NASDAQ:FUFU), Milestone Pharmaceuticals (NASDAQ:MIST) - benzinga.com
Milestone (MIST) wins FDA nod for CARDAMYST and maps AFib-RVR Phase 3 - Stock Titan
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):